If yes, then register now for Dotmatics Showcase, May 18, 2021. Learn more about Dotmatics and hear first-hand from our customers about their journey from selection to implementation of informatics solutions to support their varied R&D workflows.
Capture all your science | Molecules, biologics, sequences, assays, experiments, scientific images, text and data
Collaborate effectively | Web-based solution supports cross-team and external partner workflows
Make fully informed decisions | Use real time scientific results for data-driven decision making
Maximize your efficiency | Enable researchers to concentrate on the science by automating data flows
*Please note, the topics covered during this event are an introduction to Dotmatics and our solutions and therefore not recommended for existing customers.
|Opening & Welcome||Stephen Gallagher, Co-Founder, Dotmatics|
|Introduction to Dotmatics||Rob Brown, VP Product Marketing, Dotmatics|
|Our Dotmatics Journey from Startup to Sale||Bob Coner, Independent Informatics Consultant|
|Dotmatics Suite to Support Start-Up||Hanh Nguyen, Director, Medicinal Chemistry, Cerevel Therapeutics|
|Software Demonstration||Philip Mounteney, Head of Application Science North America and Asia Pacific, Dotmatics|
|Wrap Up||Margaret DiFilippo, VP Operations, North America, Dotmatics|
Steve Gallagher, along with co-Founder Alastair Hill, has taken Dotmatics from a scientific software start-up company to a multi-million dollar business supporting the world’s leading pharmaceutical, biotechnology and chemicals companies. Inspired by his experience as an end-user Data Scientist, Steve has always believed in providing researchers with access to all of their data, all of the time.
Steve founded Dotmatics following eight years’ industrial and academic experience. He provided research IT solutions to R&D teams as a Senior Systems Analyst at Merck Pharmaceuticals, MSD from 2000 to 2005. Prior to that Steve held a post-doctoral research position at Los Alamos Research Laboratory from 1997 to 2000 which reinforced his belief in the importance of collaborative research, across both geographies and domains. He holds a PhD in Biochemistry from the University of Warwick.
Rob previously spent 10 years at Biovia (formerly Accelrys) where he was responsible for the product marketing teams for cheminformatics, and bioinformatics for the Life Sciences industries. Prior to its acquisition by Accelrys, Rob was the Director of Product Marketing for Pipeline Pilot at Scitegic. He also held positions at MSI and Abbott Laboratories. Rob received his PhD in Cheminformatics from the University of Sheffield, UK under the direction of Prof Peter Willett.
I have worked at Dotmatics since April of 2015 and I run operations in North America. I am responsible for ensuring that customers are provided with the highest quality sales experience and see the value that Dotmatics products and services can provide. I work very closely with Phil Mounteney who heads the North America application scientist team to provide demonstrations on how our software can meet your needs. I am surrounded by very experienced sales professionals such as John Kressman who runs the western region, Vince Paton who runs strategic accounts on the east coast and Kevin Ruff who manages the non-life sciences accounts throughout North America.
I have had the pleasure of working for Dotmatics for 12 years and have spent the last 8 years in the USA leading the pre (Jess Sager) & post (Chrisandra Bright) sales teams of application scientists, support specialists (Theresa Smith) and project managers (Ania Plona) for both North America and APAC. I have an incredible team of scientists with huge breadth and depth of knowledge across Chemistry/Chemicals and Materials (Wendy Harrison) and Biologics (Steve Manning), Biology and Screening , informatics and beyond. My team is the interface between the Dotmatics developers and our customers and drives value for our users by understanding their unique needs and finding software solutions to make their research more efficient. We work closely with our sales, marketing, product management and development departments to bring customer trends, needs and cutting-edge research into the Dotmatics platform. Finally, and most importantly, my team views our customers as partners; we strive to assist throughout the life cycle of being a Dotmatics customer in a helpful and collaborative manor that provides real value and long-term success.
Hanh Nho Nguyen is Director of Medicinal Chemistry at Cerevel Therapeutics, LLC. where his team is focused on developing new therapies to treat disorders of the central nervous system (CNS). Hanh is an innovative scientific leader with a strong track record of leading internal and external chemistry teams to initiate, build and develop lead series from hit to clinical candidate selection with demonstrated expertise in drug conjugate and small molecule (SM) drug discovery across disease areas. Prior to joining Cerevel he has held positions at BlinkBio where he developed their Tunable Drug Conjugate (TDC) platform and Amgen where he was a key contributor to the identification, nomination, and preclinical scale-up of clinical candidate AMG 900. Hahn has an equally impressive academic career with a Postdoctoral position at MIT following a PhD awarded by the University of Michigan
Bob Coner has more than 20 years of experience developing and deploying informatics systems for large pharmaceutical companies (Eli Lilly, Pfizer) and start up biotechnology companies (Peloton Therapeutics and other biotech clients). Bob has managed informatics, data capture, and analysis projects deployed to a user base of ~1700 scientists distributed across 7 sites in North America, Asia, and Europe. He also created a "from scratch" data capture and analysis infrastructure for Peloton Therapeutics based on Dotmatics. Peloton used this system to manage all preclinical data for Belzutifan (PT-2977/MK-6482) which was sold to Merck for up to $2.2 Billion and was recently granted Breakthrough Therapy and Orphan Drug designations in addition to Priority Review status by the FDA.